Lung cancer is the leading cause of cancer-related mortality worldwide. Treatment with
immunotherapy has made a significant impact on the outcomes for those patients suffering …

Introduction: The recent emergence of immune checkpoint blockade therapy and the
progression of immunobiology in cancer have spurred an increasing interest in the …

The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major
changes to the therapeutic landscape of lung cancer. Improvements in overall survival …

Immune checkpoint inhibition as a new treatment approach is undergoing extensive
investigation in non–small cell lung cancer (NSCLC) and other malignancies. Unlike …

Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent
years, however, immune checkpoint inhibitors have emerged as promising therapeutic …

Immune checkpoint inhibition with blocking antibodies that target cytotoxic T-lymphocyte
antigen-4 (CTLA-4) and the programmed cell death protein 1 (PD-1) pathway [PD …

Monoclonal antibodies that target immune checkpoint proteins, so-called immune
checkpoint inhibitors, prevent tumor evasion of the immune system and are often effective in …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

The treatment of lung cancer has changed drastically in recent years owing to the advent of
immune checkpoint inhibitors (ICIs). A 1992 study reported that programmed cell death-1 …

Abstract Background: Non-Small Cell Lung Cancer (NSCLC) is one of the most prevalent
malignancies globally, accounting for 85% of lung cancer cases. The rapid advancements in …